Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease
Compassionate Use of Deferiprone in Patients With Thalassemia and Iron-Induced Heart Disease
Sponsor: ApoPharma
A observational or N/A phase clinical study on Iron Overload, this trial is ongoing. The trial is conducted by ApoPharma and has accumulated 7 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Approved For Marketing
-
Jul 2024 — Sep 2024 [monthly]
Approved For Marketing
-
Jan 2021 — Jul 2024 [monthly]
Approved For Marketing
-
Jun 2018 — Jan 2021 [monthly]
Approved For Marketing
-
Apr 2018 — Jun 2018 [monthly]
Approved For Marketing
Phase: NA → None
▶ Show 2 earlier versions
-
Feb 2017 — Apr 2018 [monthly]
Approved For Marketing NA
-
Jan 2017 — Feb 2017 [monthly]
Approved For Marketing NA
First recorded
Mar 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ApoPharma
- Children's Hospital of Philadelphia
For direct contact, visit the study record on ClinicalTrials.gov .